Notice of Extraordinary General Meeting of Infant Bacterial Therapeutics
May 16, 2023 17:31 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Extraordinary General Meeting to be held on Friday June 9, 2023 at 10.00...
Kallelse till extra bolagsstämma i Infant Bacterial Therapeutics
May 16, 2023 17:31 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), org.nr 556873-8586, med säte i Stockholm, kallar till extra bolagsstämma fredagen den 9 juni 2023 kl. 10.00 i bolagets lokaler på Bryggargatan 10, Stockholm. ...
IBT resolves on a rights issue
May 16, 2023 17:00 ET
|
Infant Bacterial Therapeutics AB
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND,...
IBT beslutar om en företrädesemisson
May 16, 2023 17:00 ET
|
Infant Bacterial Therapeutics AB
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, NYA ZEELAND, HONGKONG, JAPAN, SCHWEIZ, SINGAPORE, SYDAFRIKA,...
Annual General Meeting of Infant Bacterial Therapeutics
May 08, 2023 11:25 ET
|
Infant Bacterial Therapeutics AB
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2023, among other things, the following was resolved: to adopt the income statement and balance sheet and the...
Årsstämma i Infant Bacterial Therapeutics
May 08, 2023 11:25 ET
|
Infant Bacterial Therapeutics AB
På årsstämman i Infant Bacterial Therapeutics AB (publ) den 8 maj 2023 beslutades bland annat följande: fastställande av resultaträkningen och balansräkningen samt koncernresultaträkningen och...
Infant Bacterial Therapeutics AB (publ), Interim report January 1-March 31, 2023
May 08, 2023 07:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO Significant advancements have been made in the development of microbiome-based pharmaceuticals in the past few months. Ferring/Rebiotics' product REBYOTA™ was approved by the...
Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari – 31 mars 2023
May 08, 2023 07:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar Under de senaste månaderna har det skett betydelsefulla framsteg inom utvecklingen av mikrobiom-läkemedel. Ferrings/Rebiotics produkt REBYOTA™ godkändes av FDA i slutet av förra året...
Notice of Annual General Meeting of Infant Bacterial Therapeutics
April 03, 2023 05:20 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Annual General Meeting to be held on May 8, 2023 at 15.00 CEST at Westmanska...
Kallelse till årsstämma i Infant Bacterial Therapeutics
April 03, 2023 05:20 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), org.nr 556873-8586, med säte i Stockholm, kallar till årsstämma den 8 maj 2023 kl. 15.00 på Westmanska Palatset, konferensrum Bryggarkungen, Holländargatan 17,...